Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation
This single centre study assessed the incidence, kinetics and predictive factors of EBV reactivation and EBV-related lymphoproliferative diseases (LPD) in 33 consecutive patients who received a reduced intensity conditioning (RIC) before umbilical cord blood transplantation (UCBT). During the first...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2012-02, Vol.47 (2), p.251-257 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 257 |
|---|---|
| container_issue | 2 |
| container_start_page | 251 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 47 |
| creator | Peric, Z Cahu, X Chevallier, P Brissot, E Malard, F Guillaume, T Delaunay, J Ayari, S Dubruille, V Le Gouill, S Mahé, B Gastinne, T Blin, N Saulquin, B Harousseau, J-L Moreau, P Coste-Burel, M Imbert-Marcille, B-M Mohty, M |
| description | This single centre study assessed the incidence, kinetics and predictive factors of EBV reactivation and EBV-related lymphoproliferative diseases (LPD) in 33 consecutive patients who received a reduced intensity conditioning (RIC) before umbilical cord blood transplantation (UCBT). During the first 6 months after UCBT, weekly all patients were DNA-PCR screened in the peripheral blood for EBV reactivation and were clinically monitored for clinical features attributable to EBV. The cumulative incidences of EBV reactivation (defined as an EBV load >1000 EBV copies per 10
5
cells measured at least once during follow-up) at 6 months and 2 years after UCBT were 9 (95% confidence interval (CI), 2–22%) and 17% (95% CI, 6–33%), respectively. In 28 patients (85%), the EBV load remained negative at all times, and none of these patients experienced any sign of LPD. Five patients (15%) experienced at least one EBV reactivation episode. EBV reactivation was observed at a median of 132 days (range, 85–438) after UCBT. Two patients developed EBV-related LPD (cumulative incidence, 6% at 3 years). With a median follow-up of 468 days (range, 92–1277) post UCBT, the OS was 62% at 3 years. Five patients died of disease progression and seven patients died of transplant-related complications, including one case of EBV-related LPD. Univariate analysis did not identify any significant risk factor associated with EBV reactivation. We conclude that patients undergoing RIC UCBT are at risk for EBV reactivation, with the need for close EBV monitoring and the use of preemptive rituximab treatment as some cases may progress to life-threatening LPD. |
| doi_str_mv | 10.1038/bmt.2011.64 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_968171645</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A281111968</galeid><sourcerecordid>A281111968</sourcerecordid><originalsourceid>FETCH-LOGICAL-c643t-6f33d552dc5a2ca599bdd67a27c61c7dae4f04d17be3138fe00d4be088beadba3</originalsourceid><addsrcrecordid>eNqF0kGP1CAUAGBiNO44evJuGo160I5AgbbHdbOrJpt4Ua8NhddZNi2MQE323_vqjLuuWWN7KKEfD3jvEfKU0Q2jVfOun_KGU8Y2StwjKyZqVcpKyftkRblqyqpS7RF5lNIlpUwIKh-SI44D1sp2RXZnoPMcIRVhKE7ffysiaJPdD51d8IUeMkScsrMBWzifwSeXrwoTvHWLcH5bzD7CqDOCeerd6IweEURb9GMItshR-7Qbtc-_Yj4mDwY9Jnhy-K7J17PTLycfy_PPHz6dHJ-XRokql2qoKislt0ZqbrRs295aVWteG8VMbTWIgQrL6h4qVjUDUGpFD7RpetC219WavN7H3cXwfYaUu8klAyMeBMKculY1rGZKyP9LTutG1XyRz_-Sl2GOHq-xIC5a1tSIXvwLcSU4l4Jj2a7VVo_QOT8EzJNZNu6OecPwwQOi2tyh8LUwOSwCDA7nby149ceCC9BjvkhhnJfMp9vwzR6aGFKKMHS76CYdrzpGu6WtOmyrbmmrDuuxJs8Od5r7Cey1_d1HCF4egE5Y_wFrbly6cbKmvJVLoLd7l_CX30K8Sc5d-_4E78LirQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642254210</pqid></control><display><type>article</type><title>Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Peric, Z ; Cahu, X ; Chevallier, P ; Brissot, E ; Malard, F ; Guillaume, T ; Delaunay, J ; Ayari, S ; Dubruille, V ; Le Gouill, S ; Mahé, B ; Gastinne, T ; Blin, N ; Saulquin, B ; Harousseau, J-L ; Moreau, P ; Coste-Burel, M ; Imbert-Marcille, B-M ; Mohty, M</creator><creatorcontrib>Peric, Z ; Cahu, X ; Chevallier, P ; Brissot, E ; Malard, F ; Guillaume, T ; Delaunay, J ; Ayari, S ; Dubruille, V ; Le Gouill, S ; Mahé, B ; Gastinne, T ; Blin, N ; Saulquin, B ; Harousseau, J-L ; Moreau, P ; Coste-Burel, M ; Imbert-Marcille, B-M ; Mohty, M</creatorcontrib><description>This single centre study assessed the incidence, kinetics and predictive factors of EBV reactivation and EBV-related lymphoproliferative diseases (LPD) in 33 consecutive patients who received a reduced intensity conditioning (RIC) before umbilical cord blood transplantation (UCBT). During the first 6 months after UCBT, weekly all patients were DNA-PCR screened in the peripheral blood for EBV reactivation and were clinically monitored for clinical features attributable to EBV. The cumulative incidences of EBV reactivation (defined as an EBV load >1000 EBV copies per 10
5
cells measured at least once during follow-up) at 6 months and 2 years after UCBT were 9 (95% confidence interval (CI), 2–22%) and 17% (95% CI, 6–33%), respectively. In 28 patients (85%), the EBV load remained negative at all times, and none of these patients experienced any sign of LPD. Five patients (15%) experienced at least one EBV reactivation episode. EBV reactivation was observed at a median of 132 days (range, 85–438) after UCBT. Two patients developed EBV-related LPD (cumulative incidence, 6% at 3 years). With a median follow-up of 468 days (range, 92–1277) post UCBT, the OS was 62% at 3 years. Five patients died of disease progression and seven patients died of transplant-related complications, including one case of EBV-related LPD. Univariate analysis did not identify any significant risk factor associated with EBV reactivation. We conclude that patients undergoing RIC UCBT are at risk for EBV reactivation, with the need for close EBV monitoring and the use of preemptive rituximab treatment as some cases may progress to life-threatening LPD.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2011.64</identifier><identifier>PMID: 21441959</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adolescent ; Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood ; Bone marrow ; Bone marrow transplantation ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Cell Biology ; Complications ; Conditioning ; Confidence intervals ; Cord blood ; Cord Blood Stem Cell Transplantation - adverse effects ; Cord Blood Stem Cell Transplantation - methods ; Deoxyribonucleic acid ; DNA ; Epstein-Barr virus ; Epstein-Barr virus diseases ; Epstein-Barr Virus Infections - drug therapy ; Epstein-Barr Virus Infections - etiology ; Epstein-Barr Virus Infections - immunology ; Epstein-Barr Virus Infections - virology ; Fatalities ; Female ; Hematologic Neoplasms - surgery ; Hematologic Neoplasms - virology ; Hematology ; Hematopoietic stem cells ; Herpesvirus 4, Human - immunology ; Herpesvirus 4, Human - physiology ; Humans ; Immunoproliferative diseases ; Incidence ; Infectious diseases ; Internal Medicine ; Kinetics ; Lymphocytes ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; original-article ; Patients ; Peripheral blood ; Preempting ; Public Health ; Retrospective Studies ; Risk analysis ; Risk factors ; Rituximab ; Stem cell transplantation ; Stem Cells ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation ; Transplantation Conditioning - adverse effects ; Transplantation Conditioning - methods ; Transplants & implants ; Treatment Outcome ; Umbilical cord ; Viral diseases ; Virus Activation</subject><ispartof>Bone marrow transplantation (Basingstoke), 2012-02, Vol.47 (2), p.251-257</ispartof><rights>Macmillan Publishers Limited 2012</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2012 Nature Publishing Group</rights><rights>Macmillan Publishers Limited 2012.</rights><rights>Copyright Nature Publishing Group Feb 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c643t-6f33d552dc5a2ca599bdd67a27c61c7dae4f04d17be3138fe00d4be088beadba3</citedby><cites>FETCH-LOGICAL-c643t-6f33d552dc5a2ca599bdd67a27c61c7dae4f04d17be3138fe00d4be088beadba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/bmt.2011.64$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/bmt.2011.64$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25702954$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21441959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peric, Z</creatorcontrib><creatorcontrib>Cahu, X</creatorcontrib><creatorcontrib>Chevallier, P</creatorcontrib><creatorcontrib>Brissot, E</creatorcontrib><creatorcontrib>Malard, F</creatorcontrib><creatorcontrib>Guillaume, T</creatorcontrib><creatorcontrib>Delaunay, J</creatorcontrib><creatorcontrib>Ayari, S</creatorcontrib><creatorcontrib>Dubruille, V</creatorcontrib><creatorcontrib>Le Gouill, S</creatorcontrib><creatorcontrib>Mahé, B</creatorcontrib><creatorcontrib>Gastinne, T</creatorcontrib><creatorcontrib>Blin, N</creatorcontrib><creatorcontrib>Saulquin, B</creatorcontrib><creatorcontrib>Harousseau, J-L</creatorcontrib><creatorcontrib>Moreau, P</creatorcontrib><creatorcontrib>Coste-Burel, M</creatorcontrib><creatorcontrib>Imbert-Marcille, B-M</creatorcontrib><creatorcontrib>Mohty, M</creatorcontrib><title>Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>This single centre study assessed the incidence, kinetics and predictive factors of EBV reactivation and EBV-related lymphoproliferative diseases (LPD) in 33 consecutive patients who received a reduced intensity conditioning (RIC) before umbilical cord blood transplantation (UCBT). During the first 6 months after UCBT, weekly all patients were DNA-PCR screened in the peripheral blood for EBV reactivation and were clinically monitored for clinical features attributable to EBV. The cumulative incidences of EBV reactivation (defined as an EBV load >1000 EBV copies per 10
5
cells measured at least once during follow-up) at 6 months and 2 years after UCBT were 9 (95% confidence interval (CI), 2–22%) and 17% (95% CI, 6–33%), respectively. In 28 patients (85%), the EBV load remained negative at all times, and none of these patients experienced any sign of LPD. Five patients (15%) experienced at least one EBV reactivation episode. EBV reactivation was observed at a median of 132 days (range, 85–438) after UCBT. Two patients developed EBV-related LPD (cumulative incidence, 6% at 3 years). With a median follow-up of 468 days (range, 92–1277) post UCBT, the OS was 62% at 3 years. Five patients died of disease progression and seven patients died of transplant-related complications, including one case of EBV-related LPD. Univariate analysis did not identify any significant risk factor associated with EBV reactivation. We conclude that patients undergoing RIC UCBT are at risk for EBV reactivation, with the need for close EBV monitoring and the use of preemptive rituximab treatment as some cases may progress to life-threatening LPD.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Cell Biology</subject><subject>Complications</subject><subject>Conditioning</subject><subject>Confidence intervals</subject><subject>Cord blood</subject><subject>Cord Blood Stem Cell Transplantation - adverse effects</subject><subject>Cord Blood Stem Cell Transplantation - methods</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Epstein-Barr virus</subject><subject>Epstein-Barr virus diseases</subject><subject>Epstein-Barr Virus Infections - drug therapy</subject><subject>Epstein-Barr Virus Infections - etiology</subject><subject>Epstein-Barr Virus Infections - immunology</subject><subject>Epstein-Barr Virus Infections - virology</subject><subject>Fatalities</subject><subject>Female</subject><subject>Hematologic Neoplasms - surgery</subject><subject>Hematologic Neoplasms - virology</subject><subject>Hematology</subject><subject>Hematopoietic stem cells</subject><subject>Herpesvirus 4, Human - immunology</subject><subject>Herpesvirus 4, Human - physiology</subject><subject>Humans</subject><subject>Immunoproliferative diseases</subject><subject>Incidence</subject><subject>Infectious diseases</subject><subject>Internal Medicine</subject><subject>Kinetics</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>original-article</subject><subject>Patients</subject><subject>Peripheral blood</subject><subject>Preempting</subject><subject>Public Health</subject><subject>Retrospective Studies</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Rituximab</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation</subject><subject>Transplantation Conditioning - adverse effects</subject><subject>Transplantation Conditioning - methods</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><subject>Umbilical cord</subject><subject>Viral diseases</subject><subject>Virus Activation</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0kGP1CAUAGBiNO44evJuGo160I5AgbbHdbOrJpt4Ua8NhddZNi2MQE323_vqjLuuWWN7KKEfD3jvEfKU0Q2jVfOun_KGU8Y2StwjKyZqVcpKyftkRblqyqpS7RF5lNIlpUwIKh-SI44D1sp2RXZnoPMcIRVhKE7ffysiaJPdD51d8IUeMkScsrMBWzifwSeXrwoTvHWLcH5bzD7CqDOCeerd6IweEURb9GMItshR-7Qbtc-_Yj4mDwY9Jnhy-K7J17PTLycfy_PPHz6dHJ-XRokql2qoKislt0ZqbrRs295aVWteG8VMbTWIgQrL6h4qVjUDUGpFD7RpetC219WavN7H3cXwfYaUu8klAyMeBMKculY1rGZKyP9LTutG1XyRz_-Sl2GOHq-xIC5a1tSIXvwLcSU4l4Jj2a7VVo_QOT8EzJNZNu6OecPwwQOi2tyh8LUwOSwCDA7nby149ceCC9BjvkhhnJfMp9vwzR6aGFKKMHS76CYdrzpGu6WtOmyrbmmrDuuxJs8Od5r7Cey1_d1HCF4egE5Y_wFrbly6cbKmvJVLoLd7l_CX30K8Sc5d-_4E78LirQ</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Peric, Z</creator><creator>Cahu, X</creator><creator>Chevallier, P</creator><creator>Brissot, E</creator><creator>Malard, F</creator><creator>Guillaume, T</creator><creator>Delaunay, J</creator><creator>Ayari, S</creator><creator>Dubruille, V</creator><creator>Le Gouill, S</creator><creator>Mahé, B</creator><creator>Gastinne, T</creator><creator>Blin, N</creator><creator>Saulquin, B</creator><creator>Harousseau, J-L</creator><creator>Moreau, P</creator><creator>Coste-Burel, M</creator><creator>Imbert-Marcille, B-M</creator><creator>Mohty, M</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20120201</creationdate><title>Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation</title><author>Peric, Z ; Cahu, X ; Chevallier, P ; Brissot, E ; Malard, F ; Guillaume, T ; Delaunay, J ; Ayari, S ; Dubruille, V ; Le Gouill, S ; Mahé, B ; Gastinne, T ; Blin, N ; Saulquin, B ; Harousseau, J-L ; Moreau, P ; Coste-Burel, M ; Imbert-Marcille, B-M ; Mohty, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c643t-6f33d552dc5a2ca599bdd67a27c61c7dae4f04d17be3138fe00d4be088beadba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Cell Biology</topic><topic>Complications</topic><topic>Conditioning</topic><topic>Confidence intervals</topic><topic>Cord blood</topic><topic>Cord Blood Stem Cell Transplantation - adverse effects</topic><topic>Cord Blood Stem Cell Transplantation - methods</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Epstein-Barr virus</topic><topic>Epstein-Barr virus diseases</topic><topic>Epstein-Barr Virus Infections - drug therapy</topic><topic>Epstein-Barr Virus Infections - etiology</topic><topic>Epstein-Barr Virus Infections - immunology</topic><topic>Epstein-Barr Virus Infections - virology</topic><topic>Fatalities</topic><topic>Female</topic><topic>Hematologic Neoplasms - surgery</topic><topic>Hematologic Neoplasms - virology</topic><topic>Hematology</topic><topic>Hematopoietic stem cells</topic><topic>Herpesvirus 4, Human - immunology</topic><topic>Herpesvirus 4, Human - physiology</topic><topic>Humans</topic><topic>Immunoproliferative diseases</topic><topic>Incidence</topic><topic>Infectious diseases</topic><topic>Internal Medicine</topic><topic>Kinetics</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>original-article</topic><topic>Patients</topic><topic>Peripheral blood</topic><topic>Preempting</topic><topic>Public Health</topic><topic>Retrospective Studies</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Rituximab</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation</topic><topic>Transplantation Conditioning - adverse effects</topic><topic>Transplantation Conditioning - methods</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><topic>Umbilical cord</topic><topic>Viral diseases</topic><topic>Virus Activation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peric, Z</creatorcontrib><creatorcontrib>Cahu, X</creatorcontrib><creatorcontrib>Chevallier, P</creatorcontrib><creatorcontrib>Brissot, E</creatorcontrib><creatorcontrib>Malard, F</creatorcontrib><creatorcontrib>Guillaume, T</creatorcontrib><creatorcontrib>Delaunay, J</creatorcontrib><creatorcontrib>Ayari, S</creatorcontrib><creatorcontrib>Dubruille, V</creatorcontrib><creatorcontrib>Le Gouill, S</creatorcontrib><creatorcontrib>Mahé, B</creatorcontrib><creatorcontrib>Gastinne, T</creatorcontrib><creatorcontrib>Blin, N</creatorcontrib><creatorcontrib>Saulquin, B</creatorcontrib><creatorcontrib>Harousseau, J-L</creatorcontrib><creatorcontrib>Moreau, P</creatorcontrib><creatorcontrib>Coste-Burel, M</creatorcontrib><creatorcontrib>Imbert-Marcille, B-M</creatorcontrib><creatorcontrib>Mohty, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peric, Z</au><au>Cahu, X</au><au>Chevallier, P</au><au>Brissot, E</au><au>Malard, F</au><au>Guillaume, T</au><au>Delaunay, J</au><au>Ayari, S</au><au>Dubruille, V</au><au>Le Gouill, S</au><au>Mahé, B</au><au>Gastinne, T</au><au>Blin, N</au><au>Saulquin, B</au><au>Harousseau, J-L</au><au>Moreau, P</au><au>Coste-Burel, M</au><au>Imbert-Marcille, B-M</au><au>Mohty, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>47</volume><issue>2</issue><spage>251</spage><epage>257</epage><pages>251-257</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>This single centre study assessed the incidence, kinetics and predictive factors of EBV reactivation and EBV-related lymphoproliferative diseases (LPD) in 33 consecutive patients who received a reduced intensity conditioning (RIC) before umbilical cord blood transplantation (UCBT). During the first 6 months after UCBT, weekly all patients were DNA-PCR screened in the peripheral blood for EBV reactivation and were clinically monitored for clinical features attributable to EBV. The cumulative incidences of EBV reactivation (defined as an EBV load >1000 EBV copies per 10
5
cells measured at least once during follow-up) at 6 months and 2 years after UCBT were 9 (95% confidence interval (CI), 2–22%) and 17% (95% CI, 6–33%), respectively. In 28 patients (85%), the EBV load remained negative at all times, and none of these patients experienced any sign of LPD. Five patients (15%) experienced at least one EBV reactivation episode. EBV reactivation was observed at a median of 132 days (range, 85–438) after UCBT. Two patients developed EBV-related LPD (cumulative incidence, 6% at 3 years). With a median follow-up of 468 days (range, 92–1277) post UCBT, the OS was 62% at 3 years. Five patients died of disease progression and seven patients died of transplant-related complications, including one case of EBV-related LPD. Univariate analysis did not identify any significant risk factor associated with EBV reactivation. We conclude that patients undergoing RIC UCBT are at risk for EBV reactivation, with the need for close EBV monitoring and the use of preemptive rituximab treatment as some cases may progress to life-threatening LPD.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21441959</pmid><doi>10.1038/bmt.2011.64</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2012-02, Vol.47 (2), p.251-257 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_968171645 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Blood Bone marrow Bone marrow transplantation Bone marrow, stem cells transplantation. Graft versus host reaction Cell Biology Complications Conditioning Confidence intervals Cord blood Cord Blood Stem Cell Transplantation - adverse effects Cord Blood Stem Cell Transplantation - methods Deoxyribonucleic acid DNA Epstein-Barr virus Epstein-Barr virus diseases Epstein-Barr Virus Infections - drug therapy Epstein-Barr Virus Infections - etiology Epstein-Barr Virus Infections - immunology Epstein-Barr Virus Infections - virology Fatalities Female Hematologic Neoplasms - surgery Hematologic Neoplasms - virology Hematology Hematopoietic stem cells Herpesvirus 4, Human - immunology Herpesvirus 4, Human - physiology Humans Immunoproliferative diseases Incidence Infectious diseases Internal Medicine Kinetics Lymphocytes Male Medical sciences Medicine Medicine & Public Health Middle Aged original-article Patients Peripheral blood Preempting Public Health Retrospective Studies Risk analysis Risk factors Rituximab Stem cell transplantation Stem Cells Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation Conditioning - adverse effects Transplantation Conditioning - methods Transplants & implants Treatment Outcome Umbilical cord Viral diseases Virus Activation |
| title | Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T02%3A09%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Features%20of%20EBV%20reactivation%20after%20reduced%20intensity%20conditioning%20unrelated%20umbilical%20cord%20blood%20transplantation&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Peric,%20Z&rft.date=2012-02-01&rft.volume=47&rft.issue=2&rft.spage=251&rft.epage=257&rft.pages=251-257&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/bmt.2011.64&rft_dat=%3Cgale_proqu%3EA281111968%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2642254210&rft_id=info:pmid/21441959&rft_galeid=A281111968&rfr_iscdi=true |